

STRUCTURAL INVESTIGATION OF THE ANTIBIOTIC SPORAVIRIDIN

X¹⁾. ISOLATION AND CHARACTERIZATION OF COMPONENTS OF *N*-ACETYLSPORAVIRIDINS

KEN-ICHI HARADA, IKUMI KIMURA, ETSUKO TAKAMI and MAKOTO SUZUKI*

Faculty of Pharmacy, Meijo University,
Tempaku, Nagoya 468, Japan

(Received for publication May 29, 1984)


Isolation and characterization of the major components of *N*-acetylsporavidins, a derivative obtained by treatment of sporavidins with acetic anhydride in methanol were carried out. The isolation procedure as shown in Scheme 1 gave successfully six components whose molecular weights are all about 2,200. Each component was suggested to be a glycosidic compound consisting of a macrocyclic lactone, one of viridopentaoses, a D-glucose and an *N*-acetyl-L-vancosamine by various spectral data.

Sporavidin, the first antibiotic produced by *Streptosporangium*, is basic and water-soluble, and exhibits strong inhibitory activity against Gram-positive bacteria, yeast and trichophyton.^{2,3)} Although various structural studies have been attempted since it was isolated in 1963, its structure remains unsolved. However, it has been considered to be a glycosidic compound in view of its biological properties and preliminary structural characterization. We have recently reported on the isolation, purification and structural determination of the three constituent oligosaccharides of *N*-acetylsporavidin, designated as viridopentaoses A (1A), B (1B) and C (1C). They were established to be novel heteropentasaccharides containing two or three amino sugars on the basis of chemical degradations and spectroscopic studies.^{1,4-6)}

Very recently, sporavidin has been found to be composed of at least six closely related components (hereafter referred to as sporavidins) by chromatographic studies. In this paper we describe the isolation and characterization of the major components of *N*-acetylsporavidins.

Isolation and Characterization

The fermentation and preliminary isolation of sporavidins, and the taxonomic study of the producing strain have been already reported.^{2,3)} The sporavidin complex was obtained as a amorphous pale yellowish powder. Because of its high polarity and instability the isolation of the individual


Viridopentaose A (1A) R₁ = H, R₂ = OHViridopentaose B (1B) R₁ = H, R₂ = NHAcViridopentaose C (1C) R₁ = OH, R₂ = OH

components as intact bases has not been succeeded. Therefore, we carried out the isolation of the components of *N*-acetylsporavidins (*N*-Ac-SVD), a derivative obtained by treatment of sporavidins with acetic anhydride in methanol. The presence of three components can be clearly recognized as indicated by the thin-layer chromatograms of *N*-Ac-SVD using the combination of the two solvent systems (Fig. 1). These components were named as *N*-Ac-SVD-A, B and C. They were separated by repeated column chromatographies on silica gel (Scheme 1) and were considered to be completely isolated. However, their analytical high performance liquid chromatograms using reversed-phase ODS silica gel column indicate that each consists of further two components (Fig. 2). These two components were isolated by repeated preparative HPLC as shown in Scheme 1. Finally, each component was further purified by column chromatography on Sephadex LH-20. Thus, the isolation procedure gave six components of *N*-Ac-SVD (*N*-Ac-SVD-A₁, A₂, B₁, B₂, C₁ and C₂) as single entities in sufficient quantities for characterization. But it is hard to separate directly these six components by only preparative HPLC.

The physico-chemical properties of the thus obtained *N*-Ac-SVD are summarized in Table 1. All components were obtained as amorphous white powder. They are closely similar one another

Fig. 1. Thin-layer chromatograms of *N*-acetylsporavidins.

a: CHCl₃ - MeOH - H₂O (65: 35: 10) (lower layer).
b: EtOAc - 2-PrOH - H₂O (4: 3: 7) (upper layer).



Scheme 1. Isolation procedure for *N*-acetylsporavidins.

* HPLC condition: packing; Megapak SIL C₁₃ (7.2×250 mm), solvent; CH₃CN - H₂O (7: 3), detection; UV 232 nm, flow rate; A 5.5 ml/minute, B 4.5 ml/minute, C 3.0 ml/minute.




Fig. 2. High performance liquid chromatograms of *N*-Ac-SVD-A, B and C.
Packing; Finepak SIL C₁₈ (4.6×250 mm), flow rate; 2.5 ml/minute, solvent; CH₃CN - H₂O (7: 3),
detection; UV 232 nm.






Fig. 3. Molecular secondary ion mass spectra of *N*-Ac-SVD-C₁ and C₂.



except for their molecular weights. Although no molecular ion species were observed using glycerol matrix alone in molecular secondary ion (SI) mass spectra of these components, addition of NaCl gave reproducible results. Fig. 3 shows the molecular ion regions in the molecular SI mass spectra of *N*-Ac-SVD-C₁ and C₂ as representative examples. The sodium addition ions, $[M + Na]^+$ appear at m/z 2,242 and 2,228, indicating that the molecular weights of *N*-Ac-SVD-C₁ and C₂ are 2,219 and 2,205, respectively. Analogously, the molecular weights of other components were determined by $[M + Na]^+$ ions in their molecular SI mass spectra (Table 1).

Fig. 4. ^{13}C NMR spectra of *N*-Ac-SVD- B_1 and B_2 in CD_3OD .

The UV spectra of all components show maximums at 232 nm, which suggest the presence of a conjugated diene system in their molecules. The three characteristic bands, OH and NH groups at $3700\sim 3000\text{ cm}^{-1}$ (very strong), ester carbonyl group at 1700 cm^{-1} and amide carbonyl group at 1630 cm^{-1} are observed in the IR spectra. The ^1H NMR spectra (100 MHz, CD_3OD) are very complicated and only three or four methyl signals due to NHCOCH_3 groups can be assigned.

Fig. 4 shows the ^{13}C NMR spectra of *N*-Ac-SVD- B_1 and B_2 as typical examples. Each ^{13}C NMR spectrum contains approximate 100 signals, including four or five carbonyl, six olefinic, seven anomeric, one hemiketal and three or four glycosidation-shifted carbons. The assignable signals are summarized in Table 2. Moreover, many signals (60~80 ppm; oxymethine and oxymethylene, 25~50 ppm: methine and methylene, 10~25 ppm: methyl carbons) are observed in the upper field regions but it is almost impossible to assign these signals at present. The similar spectral behavior is shown in the

Table 2. ^{13}C NMR spectral data of *N*-acetylsporavidins.

	C=O	-C=C-	Anomeric	Hemiketal	C-O-gly
A ₁	175.0, 173.3, 173.3, 172.6	136.0, 134.8, 134.3, 133.3, 132.2, 131.8	104.7, 104.4, 103.3, 102.0×2, 100.7, 98.5	99.8	86.3, 81.9, 80.7
A ₂	175.9, 173.6, 173.5, 172.7	136.1, 134.8, 133.9, 133.0, 132.2, 131.7	104.7, 104.3, 103.3, 102.1×2, 100.7, 98.5	99.9	86.4, 82.7, 80.8
B ₁	175.1, 173.6, 173.6, 173.4, 172.6	136.0, 134.8, 134.4, 133.5, 132.2, 131.9	104.6, 104.1, 103.4, 102.0×2, 100.7, 98.5	99.9	86.2, 82.8, 80.7
B ₂	175.8, 173.6, 173.5, 173.4, 172.6	136.0, 134.8, 133.8, 133.0, 132.0, 131.6	104.7, 104.2, 103.2, 102.0×2, 100.6, 98.4	99.9	86.2, 82.7, 81.8, 80.6
C ₁	175.1, 173.6, 173.3, 172.6	136.1, 134.7, 134.3, 133.3, 132.2, 131.7	104.6, 104.1, 103.1, 102.0×2, 100.6, 98.4	99.7	86.2, 83.4, 81.1, 80.6
C ₂	175.7, 173.5, 173.3, 172.5	136.0, 134.7, 133.7, 132.9, 132.0, 131.7	104.6, 104.1, 103.1, 102.2×2, 100.4, 98.4	99.7	86.2, 83.3, 81.1, 80.0


A and C series. The resonances in the lower field regions are also listed in Table 2.

Unfortunately, antimicrobial activity of all isolated components of *N*-Ac-SVD was greatly reduced in comparison with that of sporavidins. This may be caused by the disappearance of the basicity on acetylation of amino groups in the carbohydrate moieties.

Structural Consideration

As mentioned above, each component is closely related one another and a glycosidic compounds containing seven monosaccharide units. There are three constituent amino sugars, D-acosamine (2), D-viosamine (3) and L-vancosamine (4) in their molecules.⁴⁾ Only primary amino groups in these amino sugars were acetylated under the conditions used in this study. Additionally, it was demonstrated viridopentaoses A, B and C correspond to *N*-Ac-SVD-A, B and C, respectively, and a D-glucose (5) and an *N*-acetyl-L-vancosamine (6) are common to all components by their degradative experiments.⁷⁾ Therefore, the carbohydrate moiety is composed of one of three viridopentaoses (1), a D-glucose (5) and an *N*-acetyl-L-vancosamine (6). On the other hand, the aglycone moiety has an ester or a lactone group and a hemiketal system. Two of the three double bonds form a conjugated diene in the aglycone moiety. These results suggest that *N*-Ac-SVD is a glycosidic compound consisting of a macrocyclic lactone as an aglycone.

Although several antibiotics possessing macrocyclic lactone above 30-membered ring such as copiamycin,⁸⁾ neocopiamycin,⁹⁾ scopafungin,¹⁰⁾ niphimycin,^{11,12)} azalomycin¹³⁻¹⁶⁾ and monazomycin¹⁷⁾ have hitherto been reported, no carbohydrate moieties are contained in their molecules except for monazomycin in which only one mannose is present. Recently, IKEMOTO *et al.* have reported the isolation of a sporavidin-like antibiotic, aculeximycin from the fermentation broth of *Streptospo-*



rangium albidum.^{18,19)} However, these two antibiotics were shown to be clearly differentiated from each other by direct comparison.¹⁹⁾ Consequently, sporaviridins are not related to known antibiotic families.

At present, the further elucidation for the total structures of sporaviridins is in progress.

Experimental

General

Melting points were determined on a micro-melting point apparatus (hot-stage type, Yanagimoto MP-S3) and uncorrected. Optical rotations were measured with a Jasco DIP-181 polarimeter. IR and UV spectra were determined on a Hitachi IR-215 spectrometer and a Hitachi 200-10 double beam spectrophotometer, respectively. ¹H NMR and ¹³C NMR spectra were measured on a Jeol JNM FX-100 (¹H: 100 MHz, ¹³C: 25 MHz) spectrometer using tetramethylsilane (TMS) as an internal standard. SI mass spectra were obtained using a Hitachi M-80A mass spectrometer. Operating conditions were as follows: primary ions; Xe⁺, accelerating voltage; 8 kV (primary) and 3 kV (secondary). HPLC was carried out on a Shimadzu LC-3A and Jasco Trirotar II systems with a Shimadzu SPD-2A and a Jasco Uvidec-100-II UV spectrophotometers as detectors, respectively. The separations were performed on a Jasco Finepak SIL C₁₈ (analytical) and a Jasco Megapak SIL C₁₈ (preparative). TLC was carried out on Merck pre-coated plates (Kieselgel 60 F₂₅₄). For column chromatography, Merck Kieselgel 60 (Art. 7734 and 7729) and Sephadex LH-20 (Pharmacia) were used.

N-Acetylation of SVD

A solution of sporaviridins (7 g) in dry MeOH (70 ml) was treated with acetic anhydride (35 ml). The reaction mixture was stirred overnight at room temperature and then was concentrated to dryness to yield crude *N*-Ac-SVD as a pale yellow powder (9.3 g). The crude *N*-Ac-SVD was separated as shown in Scheme 1.

Finally, each component was purified by column chromatography on Sephadex LH-20 to yield *N*-Ac-SVD-A₁, 376 mg; A₂, 546 mg; B₁, 230 mg; B₂, 222 mg; C₁, 418 mg; C₂, 625 mg.

Acknowledgments

We are indebted to Miss Y. KANO of this laboratory for technical assistance. We are also grateful to Dr. K. SHIZUKUISHI and Miss Y. NUMAJIRI of Hitachi Ltd. for obtaining the SI mass spectral data and Dr. M. HAYASHI, Toyo Jozo Ltd., for MIC measurements by the agar dilution method.

References

- 1) Part IX: HARADA, K.-I.; S. ITO, N. TAKEDA & M. SUZUKI: Structural investigation of the antibiotic sporaviridin. IX. Chemical ionization mass spectral studies of permethylated viridopentaoses and their degradation products. *Chem. Pharm. Bull.* 31: 3855~3864, 1983
- 2) OKUDA, T.; Y. ITO, T. YAMAGUCHI, T. FURUMAI, M. SUZUKI & M. TSURUOKA: Sporaviridin, a new antibiotic produced by *Streptosporangium viridogriseum* nov. sp. *J. Antibiotics, Ser. A* 19: 85~87, 1966
- 3) OKUDA, T.; T. FURUMAI, E. WATANABE, Y. OGAWA & S. KIMURA: Actinoplanaceae antibiotics. II. Studies on sporaviridin. 2. Taxonomic study on the sporaviridin-producing microorganism, *Streptosporangium viridogriseum* nov. sp. *J. Antibiotics, Ser. A* 19: 121~127, 1966
- 4) HARADA, K.-I.; S. ITO & M. SUZUKI: Structural investigation of the antibiotic sporaviridin. VI. Structures of individual sugar components. *Chem. Pharm. Bull.* 30: 4288~4296, 1982
- 5) HARADA, K.-I.; S. ITO, M. SUZUKI & T. IWASHITA: Structural investigation of the antibiotic sporaviridin. VII. Structural studies on the constituent pentasaccharides, viridopentaoses. *Chem. Pharm. Bull.* 31: 3829~3843, 1983
- 6) HARADA, K.-I.; S. ITO & M. SUZUKI: Structural investigation of the antibiotic sporaviridin. VIII. Carbon-13 nuclear magnetic resonance studies of viridopentaoses and related compounds. *Chem. Pharm. Bull.* 31: 3844~3854, 1983

- 7) HARADA, K.-I.; S. ITO & M. SUZUKI: Structural investigation of an antibiotic sporavidin. IV. Structural revision of viridopentaoses. *Tetrahedron Lett.* 23: 2479~2480, 1982
- 8) FUKUSHIMA, K.; T. ARAI, S. IWASAKI, M. NAMIKOSHI & S. OKUDA: Studies on macrocyclic lactone antibiotics. VI. Skeletal structure of copiamycin. *J. Antibiotics* 35: 1480~1494, 1982
- 9) ARAI, T.; J. UNO, I. HORIMI & K. FUKUSHIMA: Isolation of neocopiamycin A from *Streptomyces hygroscopicus* var. *crystallogenes*, the copiamycin source. *J. Antibiotics* 37: 103~109, 1984
- 10) SAMAIN, D.; J. C. COOK & K. L. RINEHART: Structure of scopafungin, a potent nonpolyene antifungal antibiotic. *J. Am. Chem. Soc.* 104: 4129~4141, 1982
- 11) BASSI, L.; B. JOOS, P. GASSMANN, H. P. KAISER, H. LEUENBERGER & W. KELLER-SCHIERLEIN: Versuche zur Strukturaufklärung von Niphimycin. 1. Reinigung und Charakterisierung der Niphimycine I α und I β sowie Abbau mit Salpetersäure. *Helv. Chim. Acta* 66: 92~117, 1983
- 12) KELLER-SCHIERLEIN, W.; B. JOOS, H. P. KAISER & P. GASSMANN: Versuche zur Strukturaufklärung von Niphimycin. 2. Die Konstitution von Desmalonyl-niphimycin I. *Helv. Chim. Acta* 66: 226~258, 1983
- 13) NAMIKOSHI, M.; K. SASAKI, Y. KOISO, K. FUKUSHIMA, S. IWASAKI, S. NOZOE & S. OKUDA: Studies on macrocyclic lactone antibiotics. I. Physicochemical properties of azalomycin F_{4a}. *Chem. Pharm. Bull.* 30: 1653~1657, 1982
- 14) NAMIKOSHI, M.; S. IWASAKI, K. SASAKI, M. AMANO, K. FUKUSHIMA, S. NOZOE & S. OKUDA: Studies on macrocyclic lactone antibiotics. II. Partial structures of azalomycin F_{4a}. *Chem. Pharm. Bull.* 30: 1658~1668, 1982
- 15) IWASAKI, S.; M. NAMIKOSHI, K. SASAKI, M. AMANO, K. FUKUSHIMA, S. NOZOE & S. OKUDA: Studies on macrocyclic lactone antibiotics. III. Skeletal structure of azalomycin F_{4a}. *Chem. Pharm. Bull.* 30: 1669~1673, 1982
- 16) IWASAKI, S.; M. NAMIKOSHI, K. SASAKI, K. FUKUSHIMA & S. OKUDA: Studies on macrocyclic lactone antibiotics. V. The structures of azalomycins F_{3a} and F_{5a}. *Chem. Pharm. Bull.* 30: 4006~4014, 1982
- 17) NAKAYAMA, H.; K. FURIHATA, H. SETO & N. ÔTAKE: Structure of monazomycin, a new ionophorous antibiotic. *Tetrahedron Lett.* 22: 5217~5220, 1981
- 18) IKEMOTO, T.; H. MATSUNAGA, K. KONISHI, T. OKAZAKI, R. ENOKITA & A. TORIKATA: Aculeximycin, a new antibiotic from *Streptosporangium albidum*. I. Taxonomy of producing organism and fermentation. *J. Antibiotics* 36: 1093~1096, 1983
- 19) IKEMOTO, T.; T. KATAYAMA, A. SHIRAIISHI & T. HANEISHI: Aculeximycin, a new antibiotic from *Streptosporangium albidum*. II. Isolation, physicochemical and biological properties. *J. Antibiotics* 36: 1097~1100, 1983